For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.

The price of Mirum Pharmaceuticals Inc (NASDAQ: MIRM) closed at $77.69 in the last session, up 0.39% from day before closing price of $77.39. In other words, the price has increased by $0.39 from its previous closing price. On the day, 0.6 million shares were traded. MIRM stock price reached its highest trading level at $77.69 during the session, while it also had its lowest trading level at $74.89.

Ratios:

We take a closer look at MIRM’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 12.82 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 452.26. For the most recent quarter (mrq), Quick Ratio is recorded 2.97 and its Current Ratio is at 3.13. In the meantime, Its Debt-to-Equity ratio is 1.25 whereas as Long-Term Debt/Eq ratio is at 1.24.

Insider Transactions:

An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 08 ’25 when SAIRA RAMASASTRY bought 17,000 shares for $77.04 per share.

Peetz Christopher sold 40,000 shares of MIRM for $2,480,000 on Aug 11 ’25. The CHIEF EXECUTIVE OFFICER now owns 138,641 shares after completing the transaction at $62.00 per share. On Aug 11 ’25, another insider, CHRISTOPHER PEETZ, who serves as the Officer of the company, bought 40,000 shares for $62.00 each.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MIRM now has a Market Capitalization of 3902959360 and an Enterprise Value of 3917308672. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.09 while its Price-to-Book (P/B) ratio in mrq is 15.24. Its current Enterprise Value per Revenue stands at 9.128 whereas that against EBITDA is -119.216.

Stock Price History:

The Beta on a monthly basis for MIRM is 0.82, which has changed by 0.85373414 over the last 52 weeks, in comparison to a change of 0.1725707 over the same period for the S&P500. Over the past 52 weeks, MIRM has reached a high of $78.10, while it has fallen to a 52-week low of $36.86. The 50-Day Moving Average of the stock is 29.09%, while the 200-Day Moving Average is calculated to be 58.50%.

Shares Statistics:

According to the various share statistics, MIRM traded on average about 611.47K shares per day over the past 3-months and 822030 shares per day over the past 10 days. A total of 50.06M shares are outstanding, with a floating share count of 40.64M. Insiders hold about 19.10% of the company’s shares, while institutions hold 94.17% stake in the company. Shares short for MIRM as of 1755216000 were 6926980 with a Short Ratio of 11.33, compared to 1752537600 on 6580855. Therefore, it implies a Short% of Shares Outstanding of 6926980 and a Short% of Float of 13.79.

Earnings Estimates

Mirum Pharmaceuticals Inc (MIRM) is currently under the scrutiny of 7.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.17, with high estimates of -$0.01 and low estimates of -$0.25.

Analysts are recommending an EPS of between -$0.51 and -$1.0 for the fiscal current year, implying an average EPS of -$0.75. EPS for the following year is -$0.09, with 8.0 analysts recommending between $0.5 and -$0.74.

Revenue Estimates

According to 7 analysts, the current quarter’s revenue is expected to be $128.93M. It ranges from a high estimate of $134.2M to a low estimate of $122.3M. As of the current estimate, Mirum Pharmaceuticals Inc’s year-ago sales were $90.38MFor the next quarter, 7 analysts are estimating revenue of $135.62M. There is a high estimate of $140.79M for the next quarter, whereas the lowest estimate is $129.7M.

A total of 8 analysts have provided revenue estimates for MIRM’s current fiscal year. The highest revenue estimate was $513.8M, while the lowest revenue estimate was $491.6M, resulting in an average revenue estimate of $503.75M. In the same quarter a year ago, actual revenue was $336.89MBased on 9 analysts’ estimates, the company’s revenue will be $598.49M in the next fiscal year. The high estimate is $650.83M and the low estimate is $558.04M.